Heliox sul lavoro respiratorio in pazienti adulti con stenosi delle vie aeree inferiori
L'effetto dell'eliox sul lavoro respiratorio nei pazienti adulti con stenosi delle vie aeree inferiori
Heliox (a mixture of Helium and Oxygen) can reduce the work of breathing in patients with airway stenosis by modifying turbulent flow into laminar flow. The aim of this study was to analyze the effect of Heliox versus conventional oxygen therapy in patients with lower airway stenosis on muscular effort measured by electromyography and diaphragmatic ultrasound, thoracoabdominal synchrony assessed with plethysmographic bands, dyspnea, stridor, oxygen saturation, transcutaneous carbon dioxide value, blood pressure, heart rate and respiratory rate.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Lower airway stenosis results in increased work of breathing with stridor and dyspnea, as a consequence of the increased resistances caused by the reduction in airway diameter. Airway resistance also depends on the length of the airway and the type of gas flow. Heliox (a mixture of Helium and Oxygen) is a gas less dense than air, which can change the flow from turbulent to laminar, reducing airway resistance by 20 to 40%, and therefore decreasing the work of breathing. Heliox is an inert gas that does not react with biological membranes, so there are few complications associated with its use, the most relevant being hypoxemia when fixed mixtures are not used and the the fraction of inspired oxygen (FiO2) supplied is less than 21%. The aim of the study was to evaluate if during the perioperative period of lower airway stenosis the administration of Heliox compared to oxygen could reduce the work of breathing and improve dyspnea. For this purpose, patients were treated for 30 minutes with Heliox (fixed mixture of 70% helium and 30% oxygen) using a non rebreather mask or reservoir bag versus 30 minutes with oxygen 31% using a Venturi mask.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
Madrid
-
Madrid, Madrid, Spagna, 28041
- Marta Corral Blanco
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients will be recluted from the pneumology outpatient clinic of the Hospital 12 de Octubre
Descrizione
Inclusion Criteria:
- Patients with lower airway stenosis evaluated at the Respiratory Endoscopy Unit of the Hospital Universitario 12 de Octubre on the waiting list for endoscopic intervention on stenosis.
- Stenosis grade ≥ 3 and Borg scale score > 2.
Exclusion Criteria:
- Presence of relevant comorbidities (uncontrolled ischemic heart disease, ventricular dysfunction, pneumopathies with severe respiratory insufficiency, severe pulmonary hypertension).
- Inability to perform the test due to severe dyspnea or need for emergency intervention.
- Patient on continuous mechanical ventilation, invasive or non-invasive.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Airway Stenosis
Patients with lower airway stenosis on waiting list for endoscopic intervention on stenosis by respiratory endoscopy unit. |
Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
Altri nomi:
Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Changes in Neural Ventilatory Drive (%):
Lasso di tempo: 30 minutes with Heliox and 30 minutes with Oxygen 31%
|
Percentage over the Root Mean Square peak for parasternal electromyography (EMG): averaged of the square root of the peak value and the area under the curve of parasternal EMG (%RootMeanSquare) adjusted for respiratory frequency, as a surrogate of diaphragmatic EMG, and sternocleidomastoid EMG, which will give us information on accessory muscle activation. |
30 minutes with Heliox and 30 minutes with Oxygen 31%
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diaphragmatic excursion assessed with ultrasound
Lasso di tempo: At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.
|
Assessment of muscular effort by measuring the diaphragmatic excursion (mm) at tidal volume and at vital capacity. |
At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.
|
|
Thickening fraction of the diaphragm assessed by ultrasound
Lasso di tempo: At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.
|
Assessment of muscular effort by measuring the thickening fraction of the diaphragm in the apposition zone (%). |
At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.
|
|
Changes in thoracoabdominal synchrony
Lasso di tempo: Phase angle was calculated from 10 consecutive breaths at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Assessment of thoracoabdominal synchrony using thoracic and abdominal belts by calculating the phase angle with the Lissajoux loop method (plotting abdominal motion on the x-axis against thoracic motion on the y-axis). |
Phase angle was calculated from 10 consecutive breaths at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
|
Borg Scale Dyspnea evolution (points)
Lasso di tempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Degree of dyspnea will be determined by this validated scale with a result between 1 and 10 points.0: Not at all 0.5: Very, very light (hardly noticeable) 1: Very light, 2: Light, 3: Moderate , 4: Somewhat intense, 5: Intense, 6: Between 5 and 7, 7: Very intense, 8: Between 7 and 9, 9: Very, very intense (almost maximum ), 10: Maximum |
Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
|
Oxygen saturation
Lasso di tempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Measured by pulse-oximetry |
Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
|
Transcutaneous partial pressure of carbon dioxide
Lasso di tempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Transcutaneous monitor uses a noninvasive technique to measure the skin-surface partial pressure of carbon dioxide (PtcCO2) |
Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
|
Blood pressure
Lasso di tempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Non-invasive measurement with a sphygmomanometer |
Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
|
Heart rate
Lasso di tempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
number of beats per minute |
Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
|
Respiratory rate
Lasso di tempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Number of breaths per minute |
Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Marta Corral Blanco, MD, Hospital 12 de Octubre
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HELIOX ON AIRWAY STENOSIS
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .